May 5, 2021 -- Athenex plans to acquire Kurr Therapeutics, including its allogeneic chimeric antigen receptor-natural killer T (CAR-NKT) cell platform, to expand its cell therapy development.
Kurr's platform aids in the development immunotherapies for the treatment of solid and hematological malignancies.
Athenex will pay $70 million upfront to Kurr shareholders, as well as some employees and directors. Additionally, they are eligible to receive up to $115 million in milestone payments. Milestone payments of cash, common stock, or combination would be made at Athenex's sole discretion.